{"product_id":"meetings-events-conference-coordinators","title":"Meetings Events \u0026 Conference Coordinators 19th Annual New Orleans Summer Cancer Meeting 2024","description":"\u003ch3 class=\"product_title entry-title\"\u003eMeetings Events \u0026amp; Conference Coordinators 19th Annual New Orleans Summer Cancer Meeting 2024\u003c\/h3\u003e\u003cbr\u003eAnnual New Orleans Summer Cancer Meeting 2024\u003cbr\u003e\u003cbr\u003e\u003cstrong\u003eInclude: 57 videos, size: 7.52 GB\u003c\/strong\u003e\n\u003cbr\u003e\u003cstrong\u003eTarget Audience: oncologists, hematologists, radiation oncologists, surgical oncologists\u003c\/strong\u003e\n\u003cbr\u003e\u003cstrong\u003eInformation:\u003c\/strong\u003e\n\u003cbr\u003e\u003cdiv class=\"form-group\"\u003e\n\u003cdiv class=\"form-control-plaintext\"\u003e\n\u003cdiv class=\"form-group\"\u003e\n\u003cbr\u003e\u003cbr\u003eThe 19th Annual New Orleans Summer Cancer Meeting (NOSCM) 2024 will take place from July 19-21, 2024, at The Roosevelt Hotel in New Orleans, Louisiana. This event will focus on improving cancer survival rates through prevention, early detection, targeted therapy, and comprehensive survivorship care. The program will cover a wide range of topics, including advancements in cancer genetics, neuro-oncology, gastrointestinal and genitourinary cancers, immunotherapy, and more.\u003cbr\u003e\u003cbr\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\u003cbr\u003eThe 19th Annual New Orleans Summer Cancer Meeting (NOSCM) 2024 is designed for a diverse group of professionals involved in oncology. The target audience includes:\u003cbr\u003e\u003cul\u003e\n\u003cli\u003eOncologists\u003c\/li\u003e\n\u003cli\u003eHematologists\u003c\/li\u003e\n\u003cli\u003eRadiation oncologists\u003c\/li\u003e\n\u003cli\u003eSurgical oncologists\u003c\/li\u003e\n\u003cli\u003eMedical oncologists\u003c\/li\u003e\n\u003cli\u003eOncology nurses\u003c\/li\u003e\n\u003cli\u003ePharmacists\u003c\/li\u003e\n\u003cli\u003eResearchers\u003c\/li\u003e\n\u003cli\u003eOther healthcare professionals involved in cancer care\u003c\/li\u003e\n\u003c\/ul\u003e\u003cbr\u003eThis meeting aims to provide the latest updates and advancements in cancer treatment, prevention, and survivorship care.\u003cbr\u003e\u003cbr\u003eAnnual New Orleans Summer Cancer Meeting 2024\u003cbr\u003e\u003cbr\u003e\u003cstrong\u003eTopics:\u003c\/strong\u003e\n\u003cbr\u003e\u003cul\u003e\n\u003cli\u003eAcquired Inhibitors in Cancer- State-of-the Art Management.mp4\u003cbr\u003eAddressing Disparities in Access to Supportive Care During Cancer Treatment and Survivorship- An Integrative Approach.mp4\u003cbr\u003eALK- First Line and Mechanism Of Resistance.mp4\u003cbr\u003eAntibody Drug Conjugates for HER2 Negative Breast Cancer- A Revolution in Chemotherapy for Breast Cancer.mp4\u003cbr\u003eApplying New Endocrine and Targeted Agents to the Treatment of Hormone Receptor Positive, HER2 Negative Breast Cancer.mp4\u003cbr\u003eArtificial Intelligence and Modern Medical Practice- Do’s and Don’ts.mp4\u003cbr\u003eBladder Cancer- Novel Insights and Recent Approvals.mp4\u003cbr\u003eCancer Care Disparities in Puerto Rico.mp4\u003cbr\u003eCancer Genetic Risk Factors- What’s New and What You Need to Know..mp4\u003cbr\u003eCAR-T Cell Therapy in Lymphomas- 7-Years Later.mp4\u003cbr\u003eChallenges in Lung Cancer Pathology- Biomarkers.mp4\u003cbr\u003eCLL- Therapeutic Advances in 2024.mp4\u003cbr\u003eColorectal Cancer- Novel Treatment Paradigms.mp4\u003cbr\u003eControversies in Colon Cancer- ctDNA in the Adjuvant Therapy of Colon Cancer and in the Management of Oligometastases (Against).mp4\u003cbr\u003eControversies in Colon Cancer- ctDNA in the Adjuvant Therapy of Colon Cancer and in the Management of Oligometastases (in Favor).mp4\u003cbr\u003eControversy in Breast Cancer- Should be pCR Be an Acceptable Endpoint for Approval of New Therapies for Early-Stage Breast Cance.mp4\u003cbr\u003eControversy in Breast Cancer- Should be pCR Be an Acceptable Endpoint for Approval of New Therapies for Early-Stage Breast Cance_2.mp4\u003cbr\u003eCost and Access to Novel Therapeutic Agents. Where Are The Obstacles..mp4\u003cbr\u003ectDNA in Lung Cancer- Current State and Future Perspectives.mp4\u003cbr\u003eDe Novo Acute Myeloid Leukemia.mp4\u003cbr\u003eDiabetes Management in the Face of Healthcare Disparities.mp4\u003cbr\u003eEGFR Exon 20 Insertions- Novel Agents.mp4\u003cbr\u003eEnd of Life Management- Oncologists’ Perspectives.mp4\u003cbr\u003eEquity and Equality for Minorities in Cancer Care.mp4\u003cbr\u003eImmunotherapy for Breast Cancer- Efficacy and Toxicity Considerations.mp4\u003cbr\u003eK-RAS Therapies in NSCLC.mp4\u003cbr\u003eKidney Cancer- Novel Development in Targeted and Immunotherapy.mp4\u003cbr\u003eLeveraging NCODA Resources to Manage Patients on Oral Oncolytics.mp4\u003cbr\u003eLifestyle Modifications in Reducing Risk of Recurrence.mp4\u003cbr\u003elos-noscm-2024-flyer.pdf\u003cbr\u003eLung Cancer With EGFR Exon 19 and L858R Mutations- The Optimal Front Line Therapy.mp4\u003cbr\u003eMalignant Hematology and Use of Bi-specifics in Puerto Rico.mp4\u003cbr\u003eMelanoma- Novel Advances in Immunotherapy.mp4\u003cbr\u003eMetastatic Castration Resistant Prostate Cancer- Sequencing the Treatment.mp4\u003cbr\u003eNavigating Mantle Cell Lymphoma in the Era of Targeted Therapy.mp4\u003cbr\u003eNeuro-Oncology- Novel Advances in Therapy.mp4\u003cbr\u003eNeurology Drug Update.mp4\u003cbr\u003eNew and Evolving Directions in the Treatment of HER2 Positive Breast Cancer.mp4\u003cbr\u003eNon Driver NSCLC-The Immunotherapy Strategy.mp4\u003cbr\u003eNovel Advances for Thyroid Carcinoma and Thymoma.mp4\u003cbr\u003eNovel Advances in T-Cell NHL Therapies.mp4\u003cbr\u003eObesity Management with Incretin Therapies- Considerations for Patients with and without Type 2 Diabetes.mp4\u003cbr\u003eOptimal Surgical Approach in Early Stages NSCLC.mp4\u003cbr\u003eOther Driver Mutations- ROS-1, BRAF, MET and RET.mp4\u003cbr\u003ePancreas, Hepatic and Cholangiocarcinoma- Advances in 2024.mp4\u003cbr\u003ePharmacology I- What HemOnc Clinicians Must Know in Immunotherapy.mp4\u003cbr\u003eProstate Cancer- Early and Locally Advanced Disease.mp4\u003cbr\u003eRole of Pharmacist in Vaccination–Challenges and Opportunities.mp4\u003cbr\u003eScreening in Lung Cancer- Challenges and Obstacles.mp4\u003cbr\u003eSequencing Therapy in Relapsed-Refractory Myeloma Patients.mp4\u003cbr\u003eSmall Cell Lung Cancer- Targeting This Difficult Target.mp4\u003cbr\u003eSoft Tissue and Osteosarcomas- Novel Advances in 2024.mp4\u003cbr\u003eTargeted Therapy in Hema Malignancies (CD20, CD30, CD33, BCR-ABL, FLT3, IDH1-2).mp4\u003cbr\u003eTesticular Cancer- The Old, The New, The Future.mp4\u003cbr\u003eUpfront Treatment for Common Ovarian Cancer (High Grade Serous) Versus Rare Histologies– Focus on PARPi and Other Targeted Ther.mp4\u003cbr\u003eUpper GI Cancer- Esophageal and Gastric-New Developments.mp4\u003cbr\u003eWhat Is Next After Osimertinib Progression..mp4\u003c\/li\u003e\n\u003c\/ul\u003e","brand":"meducours","offers":[{"title":"Default Title","offer_id":42954444537954,"sku":"MED-AMB03658","price":40.0,"currency_code":"USD","in_stock":true}],"thumbnail_url":"\/\/cdn.shopify.com\/s\/files\/1\/0662\/9549\/6802\/files\/Meetings-Events-Conference-Coordinators-19th-Annual-New-Orleans-Summer-Cancer-Meeting-2024-1.webp?v=1779376895","url":"https:\/\/meducourse.com\/products\/meetings-events-conference-coordinators","provider":"Meducourse","version":"1.0","type":"link"}